SOUTH EASTON,
MA--(Marketwired - Oct 26,
2016) - Pressure
BioSciences, Inc. (OTCQB: PBIO)
("PBI" and the "Company"), a
leader in the development
and sale of broadly enabling
pressure cycling technology
("PCT")-based sample
preparation solutions to the
large and growing worldwide
life sciences industry,
today announced its featured
participation in the recent
opening of The ACRF
International Centre for the
Proteome of Human Cancer
("ProCan"), located in newly
renovated laboratory
facilities at the Children's
Medical Research Institute
("CMRI") near Sydney,
Australia.
In addition to PBI, ProCan
and CMRI scientists,
presentations were made by
other invitees, including
representatives from SCIEX,
Ilumina, Beckman-Coulter,
and NextBio, as well as from
Dr. Tiannan Guo of Professor
Ruedi Aebersold's lab at the
world-renowned Institute of
Molecular Systems Biology
(Zurich, Switzerland).
Professor Aebersold is
generally considered to be
one of the leading
proteomics scientists in the
world.
ProCan expects to analyze a
minimum of 10,000 cancer
tumor samples per year over
the next seven years with
cutting-edge protein
analysis instruments and
other lab tools. It is
anticipated that data from
their studies will trigger
discoveries illuminating
causes of cancer, providing
invaluable guidance on
cancer treatment options and
creating a new era in
standard operating
procedures applied in cancer
testing laboratories
worldwide.
"ProCan is very simple in
concept but massive in
scale," said CMRI Director,
Professor Roger Reddel, who
is also a co-leader of
ProCan. "We believe the
results of ProCan will
greatly improve the speed
and accuracy of cancer
diagnosis and provide
clinicians an enhanced
capability to choose the
most effective treatment
option for each individual
patient's cancer and,
importantly, to avoid those
treatments that are likely
to be unsuccessful. This
will reduce treatment
toxicity and improve cancer
treatment outcomes in
children and adults --
worldwide." (Source of quote
plus more information on
ProCan and CMRI can be found
at http://www.cmri.org.au/News/Latest-News/ProCan-Officially-Opens-at-CMRI.)
In June 2016, ProCan
purchased the first three
commercially released,
next-generation PCT-based
instruments, the Barocycler
2320EXTREME (the
"2320EXT"). A short video
introducing the 2320EXT can
be viewed at https://youtu.be/xbO6Lp4VxwU.
In their planned analysis of
70,000-plus tumor samples,
ProCan will combine PBI's
Barocycler 2320EXT system
for sample preparation with
SCIEX's SWATH data
independent-acquisition mass
spectrometry workflow on
Triple TOF® 6600 Systems.
The advantages of this
method ("PCT-SWATH") have
been the focus of scientific
journal articles by Dr.
Aebersold, Dr. Guo, and
others over the past several
years.
SCIEX is a global leader in
life science analytical
technologies. In January
2016, PBI and SCIEX
announced an exclusive,
two-year, worldwide
co-marketing agreement under
which PBI and SCIEX will
co-promote PBI's PCT systems
with SCIEX's SWATH-based
proteomics workflows.
Dr. Alexander Lazarev, Vice
President of R&D at PBI
said: "We were honored when
ProCan recognized and
selected the PCT platform
for the significant
advantages in sample
preparation that it
affords. Reproducibility,
speed, automation, and
enhanced protein extraction
and digestion are all
critical elements in the
preparation of samples for
analysis. When these sample
preparation attributes of
PCT are combined with the
leading quality of SCIEX
mass spectrometers, we
believe that ProCan and
other users of PCT-SWATH
will significantly increase
their chances to discover
new and potentially
important biomarkers of
cancer."
Dr. Nate Lawrence, Vice
President of Sales and
Marketing for PBI,
commented: "CMRI was
recently named an official
collaborator of the US
National Cancer Institute's
"Cancer Moonshot"
initiative, whose goal is to
accelerate what would
normally take ten years of
cancer research into
completion in the next five
years. We believe that the
Cancer Moonshot initiative
will strategically support
and accelerate the field of
precision (personalized)
medicine through studies
such as those planned at
CMRI, which could lead to
better identification,
diagnosis, treatment, and
prevention of cancer. We are
proud to be a part of this
very important and inspiring
program."
Dr. Lawrence continued:
"Nearly $1 Billion in new
funding is planned for
cancer research in the
current US fiscal year, a
portion of which could
support the expansion of
additional "industrialized
proteomics" labs worldwide,
similar to ProCan. With the
recognition that ProCan and
other cancer research
programs are already giving
to our recently released,
next-generation 2320EXT
Barocycler system, combined
with our planned salesforce
expansion and our SCIEX
co-marketing program, we
believe we will see robustly
increasing sales of our PCT
product line in 2017 and
beyond."
About Pressure BioSciences,
Inc.
Pressure BioSciences, Inc.
("PBI") (OTCQB: PBIO)
develops, markets, and sells
proprietary laboratory
instrumentation and
associated consumables to
the estimated $6 billion
life sciences sample
preparation market. Our
products are based on the
unique properties of both
constant (i.e., static) and
alternating (i.e., pressure
cycling technology, or PCT)
hydrostatic pressure. PCT is
a patented enabling
technology platform that
uses alternating cycles of
hydrostatic pressure between
ambient and ultra-high
levels to safely and
reproducibly control
bio-molecular interactions.
To date, we have installed
over 260 PCT systems in
approximately 160 sites
worldwide. There are over
100 publications citing the
advantages of the PCT
platform over competitive
methods, many from key
opinion leaders. Our primary
application development and
sales efforts are in the
biomarker discovery and
forensics areas. Customers
also use our products in
other areas, such as drug
discovery & design,
bio-therapeutics
characterization, soil &
plant biology, vaccine
development, histology, and
forensic applications.
Forward Looking & Disclaimer / Privacy
For more information about
PBI and this press release,
please click on the
following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook,
LinkedIn, and Twitter
Visit Investors Hangout For
More Information: http://investorshangout.com/
